Evidence map›Paper›PMID 40758124›Full record

ArticleClinical pharmacology and therapeutics2025

Effectiveness and Safety of Reduced-Dose Prasugrel in an East Asian Population: PRASFIT-ACS Emulation Using National Health Insurance Claims Data.

Li-Wen Huang, Yee-Jen Wu, Fang-Ju Lin, Chien-Chih Wu, Hsin-Yi Huang, Chi-Chuan Wang, Xiaojuan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Li-Wen Huang *Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yee-Jen Wu *Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0009-0009-5675-2811
Fang-Ju LinGraduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-8249-7481
Chien-Chih WuDepartment of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-9517-2176
Hsin-Yi HuangSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-4432-1864
Chi-Chuan WangGraduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-4597-4859
Xiaojuan LiDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.ORCID 0000-0002-1305-0846

Funding

Research Continuity and Retention Supplement: Optimizing care for older adults in the new treatment era for type 2 diabetes and heart failureK01AG073651 · NIA · HARVARD PILGRIM HEALTH CARE, INC. · PI Xiaojuan Li · 2022 to 2026
$700k
National Science and Technology Council of Taiwan MOST 111-2636-B-002-019National Science and Technology Council of Taiwan NSTC 113-2320-B-002-054NIA NIH HHS K01 AG073651NIA NIH HHS K01AG073651
6 · The paper itself

Abstract

Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real-world effectiveness and safety of reduced-dose prasugrel in an East Asian population by emulating the pivotal PRASFIT-ACS trial using Taiwan's National Health Insurance claims data. In this study, ACS patients were classified into reduced-dose prasugrel or clopidogrel groups post-PCI. We estimated the intention-to-treat effect of initiating reduced-dose prasugrel vs. clopidogrel on the risk of major adverse cardiovascular events (MACE) and the per-protocol effect of treating with reduced-dose prasugrel on major bleeding risk using Cox proportional hazard models. A total of 4833 ACS patients were analyzed, including 977 (20.2%) who received reduced-dose prasugrel. Reduced-dose prasugrel showed comparable effectiveness to clopidogrel in preventing MACE (HR: 0.96, 95% CI: 0.72-1.29) and did not increase bleeding risk (HR: 0.82, 95% CI: 0.36-1.90), consistent with PRASFIT-ACS results (HR

Indexed as

Acute Coronary SyndromePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPrasugrel HydrochlorideAgedClopidogrelEast Asian PeopleFemaleHemorrhageHumansInsurance Claim ReviewMaleMiddle AgedNational Health ProgramsRetrospective StudiesTaiwanClopidogrelPlatelet Aggregation InhibitorsPrasugrel Hydrochloride

Identifiers

PMID40758124
PMCPMC12390784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.